Who Makes Colchicine and Where Does It Come From?

Colchicine is extracted from plants, not synthesized in a chemistry lab. The drug’s primary natural sources are two flowering species: the autumn crocus (Colchicum autumnale), native to Europe, and the glory lily (Gloriosa superba), found mainly in tropical Asia and Africa. Pharmaceutical manufacturers then purify the alkaloid from harvested seeds, corms, or tubers and formulate it into tablets. The story of who makes it and where it originates spans wild meadows in central Europe, commercial farms in southern India, and a surprisingly contentious chapter of American drug regulation.

The Two Plants That Supply Nearly All the World’s Colchicine

Autumn crocus is not actually a crocus at all. It belongs to the family Colchicaceae and blooms with pale purple flowers in fall, after its leaves have already died back. The plant grows across damp meadows in much of Europe, from England to the Balkans, and it produces colchicine in its seeds, corms, and leaves. Historically, it has been the primary botanical source of the drug, and European wild-collection and small-scale farming have supplied pharmaceutical-grade material for centuries.¹ The plant remains essentially undomesticated, with seeds harvested from wild or semi-wild populations and their alkaloid content varying considerably from one collection site to another.²

Glory lily (Gloriosa superba) has become the more commercially important source in recent decades, particularly in India. The plant is a climbing vine with dramatic red-and-yellow flowers, and its tubers and seeds contain colchicine along with related alkaloids. India, and especially the state of Tamil Nadu, is a major hub for glory lily cultivation. Farmers there grow it as a cash crop, harvesting the seeds for pharmaceutical extraction. The economics are substantial: per-acre profits can run well over ten lakh rupees (roughly $12,000 USD), though farmers face real volatility. Prices dropped sharply between 2021 and 2022, partly because of middlemen controlling market access and partly because of fluctuating global demand.³ Despite these swings, the crop remains attractive because of the high overall returns across multiple harvest cycles.⁴

Why Colchicine Is Extracted, Not Synthesized

Colchicine has a complex three-ring molecular structure that organic chemists have managed to build from scratch in the laboratory. Researchers have published total synthesis routes. The problem is that these syntheses involve many steps, low yields, and expensive reagents, which makes them commercially impractical.⁵ So even though we know how to make colchicine from simple starting materials in a flask, virtually every tablet on the market still traces back to plant matter. The pharmaceutical industry treats it as a natural product to be isolated and purified, not a molecule to be assembled from chemicals.

This reliance on agricultural supply introduces vulnerabilities. Weather, disease, price manipulation, and harvest timing all affect how much raw material reaches extraction facilities. It also means the drug’s cost is sensitive to agricultural economics in a handful of regions, rather than to the price of bulk chemicals.

How Extraction Works at Industrial Scale

Getting pharmaceutical-grade colchicine out of plant seeds or tubers involves grinding the plant material, pulling the alkaloid into a solvent, and then running it through purification columns. Older methods used maceration and sonication with organic solvents. Newer approaches rely on supercritical carbon dioxide extraction, which is faster and generates less chemical waste. Researchers have demonstrated that supercritical CO₂ can recover colchicine from Colchicum autumnale seeds with recovery rates above 98% for multiple alkaloids in about two hours.⁶

A similar approach has been applied to Gloriosa superba seeds. In one study, seeds containing about 0.7% colchicine by weight were processed with supercritical CO₂ using water as a co-solvent, yielding an extract with roughly 27% colchicine content. After further purification through charcoal and alumina columns, the final product reached a purity of about 99.8%.⁷ That level of purity is what pharmaceutical manufacturers need to produce consistent, safe tablets.

The Pharmaceutical Companies and the FDA Controversy

Colchicine has been used to treat gout for well over a thousand years, and for most of that time it was sold without formal regulatory approval in the United States. Doctors prescribed it, pharmacies dispensed it, and nobody had ever put it through a modern clinical trial. That changed in 2009, when URL Pharma (later acquired by Takeda Pharmaceuticals) conducted an FDA-required trial of colchicine for acute gout and received approval for the branded product Colcrys. The FDA then exercised its authority to remove unapproved colchicine products from the market, granting URL Pharma a period of market exclusivity.

The consequences were dramatic. Average monthly prescription costs for patients on colchicine jumped from about $418 to $651, and colchicine initiation rates dropped, meaning fewer new patients started on the drug.⁸ Critics argued that the FDA had effectively turned one of the oldest drugs in medicine into a new branded product and driven up prices for patients who relied on it. Supporters countered that the trial finally established proper dosing and safety data. Either way, the episode reshaped who could sell colchicine in the U.S. and at what price. Generic versions eventually entered the market after the exclusivity period, lowering costs, but the Colcrys saga remains a cautionary tale about how regulatory frameworks can interact with ancient drugs in unexpected ways.

Outside the United States, colchicine is manufactured and sold by a range of generic pharmaceutical companies, often at much lower prices. Indian manufacturers are significant players in the global supply, which makes sense given that India also produces much of the raw plant material.

What Colchicine Actually Does in the Body

The drug works by binding to a protein called tubulin, which cells need to build their internal scaffolding, known as microtubules. When colchicine blocks tubulin from assembling properly, it disrupts a chain of inflammatory processes. White blood cells lose much of their ability to migrate toward sites of inflammation, and the release of inflammatory signaling molecules drops.⁹ More recently, researchers have identified that colchicine also blocks a specific inflammatory complex called the NLRP3 inflammasome. Microtubules are needed to bring the components of this complex together inside cells, so when colchicine interferes with microtubule assembly, the whole inflammatory cascade gets turned down.¹⁰ These overlapping anti-inflammatory effects extend beyond gout to a growing list of conditions.¹¹

From Gout to Heart Disease and Beyond

The classic use of colchicine is for gout, where it calms the intense inflammation caused by urate crystals depositing in joints. It is also the go-to treatment for familial Mediterranean fever (FMF), a genetic condition that causes recurring episodes of fever and painful inflammation. For FMF, the recommended dose ranges from 1 to 3 mg per day depending on the patient’s age, weight, and disease activity.¹²

The more surprising recent development is colchicine’s emergence in cardiology. A large trial involving thousands of patients with chronic coronary disease found that low-dose colchicine reduced the risk of major cardiovascular events by about 31% compared with placebo.¹³ A meta-analysis pooling results from five randomized trials, covering nearly 12,000 patients, found a 25% reduction in major adverse cardiovascular events, a 22% reduction in heart attacks, and a striking 46% reduction in strokes among patients taking colchicine.¹⁴ The logic makes sense: atherosclerosis is partly driven by chronic inflammation, and colchicine is a potent inflammation dampener. In 2023, the FDA approved low-dose colchicine (marketed as Lodoco) specifically for reducing cardiovascular risk, making it one of the first anti-inflammatory drugs formally approved for that purpose. This cardiovascular indication has significantly widened the potential market for the drug and, by extension, the demand for raw plant material.

A Very Narrow Safety Margin

For all its therapeutic versatility, colchicine is a genuinely dangerous substance at doses not far above the therapeutic range. The gap between an effective dose and a toxic one is small. Effective blood levels sit between roughly 0.5 and 3 micrograms per liter, with toxic effects beginning right around that upper boundary.¹⁵ Fatalities have been reported with doses as low as 3 mg total, and ingestion above about 0.5 mg per kilogram of body weight is generally fatal.¹⁵

Poisoning typically unfolds in three phases. In the first 10 to 24 hours, gastrointestinal symptoms dominate: nausea, vomiting, and diarrhea. Over the next several days, organ failure can set in, including bone marrow suppression and cardiovascular collapse. If the patient survives, a recovery phase may follow after about a week. There is no antidote for colchicine poisoning. Treatment is purely supportive, and the best intervention is preventing further absorption with activated charcoal if the patient presents early enough.¹⁶ This toxicity profile is one reason why the FDA’s insistence on proper clinical trials, despite the drug’s ancient pedigree, was not entirely unreasonable.

The narrow margin also matters for interactions with other drugs. Anything that slows colchicine’s metabolism in the liver or blocks its elimination from cells can push blood levels into the danger zone. Patients taking certain antibiotics, antifungals, or heart medications need dose adjustments or should avoid colchicine altogether.

Biosynthetic Engineering and Endophytic Fungi

Given the drug’s dependence on a small number of plant species and its rising demand from the cardiovascular market, researchers have been exploring alternative production routes. One approach involves reconstructing the plant’s own biosynthetic pathway in a laboratory organism. Scientists identified the genes that autumn crocus uses to build colchicine from two amino acids, phenylalanine and tyrosine, and transferred a 16-enzyme pathway into a tobacco relative (Nicotiana benthamiana). The engineered plant successfully produced a late-stage colchicine precursor called N-formyldemecolcine.¹⁷ Getting from that precursor to colchicine itself requires additional steps that have not yet been commercially optimized, but the work represents a credible path toward producing colchicine independently of wild or farmed autumn crocus and glory lily.

Another intriguing avenue involves fungi that live inside colchicine-producing plants. Researchers isolated a fungal endophyte, Diaporthe perseae, from the tubers of Gloriosa superba and confirmed that it could produce colchicine on its own when grown in laboratory culture. The confirmation came through mass spectrometry, NMR spectroscopy, and functional assays showing that the compound disrupted tubulin assembly, just as plant-derived colchicine does.¹⁸ The challenge is that fungal cultures tend to lose their ability to produce the alkaloid over successive generations, a problem the researchers addressed by manipulating the fungus’s gene regulation. If scaled up, endophytic production could eventually reduce pressure on wild and farmed plant populations.

Colchicine Derivatives for Cancer Research

Because colchicine disrupts microtubule assembly, it has long attracted interest as a potential anti-cancer agent. Cells need microtubules to divide, and blocking their formation can halt tumor growth. However, colchicine itself is too toxic at anti-cancer doses to be safe for patients. Researchers have instead focused on modifying the molecule’s structure to retain the anti-tumor activity while reducing toxicity. Colchicine derivatives with altered chemical groups on different parts of the three-ring skeleton have been synthesized through both chemical and microbial methods, and some of these show promising anti-tumor effects with a better safety profile.¹⁹ None of these derivatives has reached mainstream clinical use for cancer treatment, but the research continues actively, and any breakthrough would further increase demand for either colchicine or its precursors.

Colchicine in Plant Breeding

One of colchicine’s most widespread uses falls entirely outside medicine. Plant breeders have relied on it for decades to create polyploid plants, which carry extra sets of chromosomes. When you apply colchicine to growing plant tissue, it prevents chromosome separation during cell division, resulting in cells with doubled chromosome numbers. Plants with extra chromosome sets often grow larger, produce bigger flowers or fruits, and sometimes show improved resistance to disease or stress.²⁰ This technique has been used to develop new varieties of ornamental plants, food crops, and medicinal herbs.²¹ Seedless watermelons, for example, are produced through a process that involves colchicine-treated parent plants. This agricultural demand represents a separate stream of consumption that runs parallel to the pharmaceutical supply chain, and it means the drug has customers in two quite different industries.

Why Supply Chain Risks Are Growing

The combination of expanding medical indications and continued agricultural use puts real pressure on the botanical supply chain. Gloriosa superba is listed as threatened or endangered in parts of its native range due to overharvesting of wild tubers, even as cultivated acreage in India has expanded. Farmers in Tamil Nadu face the double challenge of high startup costs and unpredictable market prices. The heavy involvement of intermediaries between growers and pharmaceutical buyers compresses farmer margins and can create bottlenecks in supply.³ Weather disruptions, particularly excessive rainfall and fog during growing seasons, add another layer of uncertainty.⁴

Meanwhile, Colchicum autumnale in Europe remains largely undomesticated, with significant batch-to-batch variation in alkaloid content depending on where the plants were collected and what the growing conditions were like that year.² This variability complicates quality control for manufacturers who need consistent raw material. If the cardiovascular indication drives a major increase in colchicine prescriptions worldwide, the current agricultural base may struggle to keep up without either significant expansion of cultivation, successful scaling of biosynthetic alternatives, or both.

1
PubMed Central. Toxicity and Sublethal Effects of Autumn Crocus (Colchicum autumnale) Bulb Powder on Red Imported Fire Ants (Solenopsis invicta)
2
Canadian Journal of Plant Science. Agronomical and chemical variability of Colchicum autumnale accessions
3
Current Agriculture Research Journal. Economic Viability of Glory Lily Cultivation in Western Tamil Nadu: A Comprehensive Cost-Return Analysis
4
Plant Science Today. Unveiling the economic potential of Glory Lily (Gloriosa superba) cultivation in Tamil Nadu (Dindigul district)
5
Organic Letters. Unlocking the genetic and biotechnological potential of Gloriosa superba to enhance its alkaloid production
6
PubMed. Supercritical carbon dioxide extraction of colchicine and related alkaloids from seeds of Colchicum autumnale L.
7
PubMed Central. Colchicine: Isolation, LC–MS QTof Screening, and Anticancer Activity Study of Gloriosa superba Seeds
8
PubMed Central. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population
9
PubMed. Mechanism of action of colchicine in the treatment of gout
10
PubMed Central. Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation
11
PubMed Central. Colchicine – update on mechanisms of action and therapeutic uses
12
Arthritis & Rheumatology. Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever
13
PubMed. Colchicine in Patients with Chronic Coronary Disease
14
European Heart Journal. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
15
PubMed Central. Colchicine: the good, the bad, the ugly and how to minimize the risks
16
PubMed Central. Progress in the management of acute colchicine poisoning in adults
17
PubMed Central. Discovery and engineering of colchicine alkaloid biosynthesis
18
PubMed. DNA demethylation overcomes attenuation of colchicine biosynthesis in an endophytic fungus Diaporthe
19
PubMed. Biotherapeutic potential and mechanisms of action of colchicine
20
PubMed Central. The Role of Colchicine in Plant Breeding
21
PubMed Central. Studies on Colchicine Induced Chromosome Doubling for Enhancement of Quality Traits in Ornamental Plants